In a study appearing this month in the Journal of Immunology, researchers at the University of Illinois describe how an impaired anti-inflammatory response plays a role in the pathology of type 2 diabetes.
A symposium, sponsored by the American Journal of Nursing (AJN) in collaboration with the American Diabetes Association, the American Association of Diabetes Educators, Joslin Diabetes Center and the University of Pennsylvania School of Nursing identified barriers to, and strategies for, more effective diabetes self management and reaffirmed the nurse’s critical role to facilitate better patient self care. These results are published in a special supplement to the June issue of AJN.
Diabetes is often called a lifestyle disease, and now a new study from the University of Missouri-Columbia verifies that a lifestyle change brings strong improvements.
Reducing time spent sitting and increasing light physical activity has important health benefits that may reduce the risk of diabetes and other cardiovascular diseases.
Men and women with diabetes at age 50 and older appear not to live as long overall, or have as many years without cardiovascular disease, than individuals without diabetes, according to a report in the June 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Poor glucose control is often attributed to clinical inertia: the recognition of a problem by the physician, but failing to act.
Researchers at the University of Pennsylvania School of Medicine have discovered a potential new target for treating type 2 diabetes, according to a new study that appeared online this week in Nature. The target is a protein, along with its molecular partner, that regulates fat metabolism.
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Blocking a single protein with an experimental drug prevented and treated both type 2 diabetes and atherosclerosis in laboratory mice that had been fed unhealthy diets and were genetically predisposed to these common killers, according to an article published online at Nature on June 6, 2007.
FDA has requested a black box warning for the labels of the type 2 diabetes medications Avandia, manufactured by GlaxoSmithKline, and Actos, manufactured by Takeda Pharmaceuticals, because of increased risk for congestive heart failure associated with the medications, agency Commissioner Andrew von Eschenbach announced on Wednesday at a House Oversight and Government Reform Committee hearing, the New York Times reports.